Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Oncol. May 24, 2022; 13(5): 339-351
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.339
Table 2 Primary and Secondary outcomes by potential prognostic variables (n = 123), n (%)

Admitted to ICU
Met composite endpoint
Required mechanical ventilation
Died
Total (n = 123)20 (16.2)30 (24.3)10 (8.1)18 (14.6)
Age, yr
< 65 (n = 91)18 (19.7)22 (22.2)9 (9.9)16 (17.6)
65-74 (n = 25)1 (4)5 (20)1 (4)1 (4)
≥ 75 (n = 7)1 (14.3)3 (42.8)01 (14.3)
Sex
Male (n = 59)6 (10.2)11 (18.6)3 (5)5 (8.5)
Female (n = 64)14 (21.8)19 (29.7)7 (10.9)13 (20.3)
Number of comorbidities
0 (n = 54)6 (11.1)9 (16.7)04 (7.4)
1 (n = 32)5 (15.6)11 (34.4)4 (12.5)5 (15.6)
≥ 2 (n = 37)9 (24.3)10 (27)6 (16.2)9 (24.3)
Type of malignancy
Thorax (n = 10)1 (10)2 (20)1 (10)1 (10)
GIT (n = 9)5 (55.5)6 (66.6)3 (33.3)4 (44.5)
HPB (n = 40)8 (20)14 (35)4 (10)7 (17.3)
GUT (n = 49)5 (10)7 (14.2)2 (4)5 (10)
Others (n = 15)1 (6.7)1 (6.7)01 (6.7)
Cancer status
Remission or no evidence of disease (n = 8)02 (25)00
Present, stable, or responding to treatment (n = 66)6 (9.9)9 (13.6)5 (7.6)5 (7.6)
Present, progressive disease unknown (n = 49)14 (28.6)19 (38.7)5 (10)13 (26.5)
ECOG performance status
0 or 1 (n = 90)010 (11.1)00
2 (n = 18)2 (11.1)5 (27.7)2 (11.1)4 (22.2)
≥ 3 (n = 15)15 (100)15 (100)8 (53.3)14 (93.3)
Type of anticancer therapy
None in the 4 wk before COVID-19 diagnosis (n = 14)6 (42.5)8 (57.1)3 (21.4)5 (35.7)
Non-cytotoxic therapy targeted therapy/endocrine therapy (n = 9)2 (22.2)5 (55.5)1 (11.1)2 (22.2)
Immunotherapy (n = 3)0000
Cytotoxic systemic therapy (n = 90)11 (12.2)16 (17.7)6 (6.7)10 (11.1)
External beam radiotherapy (n = 7)1 (14.3)1 (14.3)01 (14.3)
Recent surgery
None in the 4 wk before COVID-19 diagnosis (n = 113)19 (16.8)28 (24.8)9 (8)17 (15)
Yes (n = 10)1 (10)2 (20)1 (10)1 (10)
RT-PCR Test (viral load)
Mild (n = 49)5 (10.2)8 (16.3)3 (6.1)5 (10.2)
Moderate (n = 30)5 (16.7)9 (30)4 (13.3)5 (16.7)
High (n = 44)10 (22.7)13 (29.5)3 (6.8)8 (18.1)
HRCT Score
Mild (n = 77)7 (9)13 (16.9)05 (6.5)
Moderate (n = 38)7 (18.4)11 (28.9)4 (10.5)7 (18.4)
Severe (n = 8)6 (75)6 (75)6 (75)6 (75)
Treatment of COVID-19
Hydroxychloroquine (HCQ) alone, azithromycin alone or with combination HCQ/azithromycin/ivermectin (n = 22)1 (4.5)3 (13.6)01 (4.5)
+ Steroids (n = 36)4 (11.1)8 (22.2)2 (5.6)4 (11.1)
+ Remdesivir (n = 29)8 (27.6)11 (37.9)4 (13.8)7 (24.1)
+ Tocilizumab (n = 3)1 (33.3)1 (33.3)01 (33.3)
+ Plasma therapy (n = 11)6 (54.4)7 (63.6)4 (36.6)4 (36.6)
Neither (n = 22)0000